Chaudhuri A, Behan PO (2005) Treatment of multiple sclerosis: beyond the NICE guidelines. QJM 98:373-378Chaudhuri A, Behan PO. Treatment of multiple sclerosis: beyond the NICE guidelines. QJM 2005 May; 98(5): 373–8A. CHAUDHURI,P.O. BEHAN.Treatment of multiple sclerosis: beyond the NICE...
The National Institute for Clinical Excellence (NICE) in England and Wales has been appraising the evidence on the clinical and cost effectiveness of IFN-... A Clegg,J Bryant - 《Expert Opinion on Pharmacotherapy》 被引量: 75发表: 2001年 Immunomodulatory drugs for multiple sclerosis: a systemati...
It also does not cover symptomatic treatments, rehabilitation or disorders other than multiple sclerosis. The version of guidelines agreed by the authors were reviewed by 15 UAE neurologists with expertise in MS (see acknowledgements) and their suggestions incorporated where possible to form the final...
Prior to the era of disease-modifying therapies (DMT), multiple sclerosis (MS) was linked to reduced rates of cancer. Early use of immunosuppressors (IS) in MS justifies the follow-up of patients to evaluate a possible increase in the incidence of cancer in these patients. We performed a ...
Multiple Sclerosis Society UK, Mums Like Us, National Childbirth Trust, National Kidney Federation, Perinatal Mental Health Research (Facebook), Polycystic Kidney Disease Charity, Positive Birth Edinburgh, Positive Birth Scotland: Hypnobirthing and Birth Preparation, Psoriasis Association, Raham Project, ...
NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales. This ruling means that there will be a divide in access to Zeposia in the UK, after the Scott
Cognitive impairment is a common and devastating manifestation of multiple sclerosis (MS). Although disease-modifying therapies have been efficacious for reducing relapse rates in MS, such treatments are ineffective for treating cognitive dysfunction. Al
The multiple sclerosis condition center is a resource for clinical news on the diagnosis, treatment, and management of multiple sclerosis. | NeurologyLive.
Astrocytes are a major cellular component of the brain that are capable of intense proliferation and metabolic activity during diverse inflammatory brain diseases (such as multiple sclerosis, Alzheimer's dementia, tumor, HIV encephalitis, or prion disease). In this biological process, called reactive ...
CI indicates confidence interval; CLARITY, Cladribine Tablets Treating Multiple Sclerosis Orally (trial); HR, hazard ratio; IPCW, inverse probability of censoring weights; ITT, intention to treat; LL, low-dose cladribine in CLARITY; LLPP, low-dose cladribine in CLARITY followed by placebo in CLARIT...